A Comprehensive Review of PCSK9 Inhibitors
Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. A major risk factor for this condition is increased serum low-density lipoprotein cholesterol (LDL-C) levels for which statins have been successful in reducing serum LDL-C to healthy concentrations. Howeve...
Saved in:
Main Authors: | Caroline Coppinger BS (Author), Mohammad Reza Movahed MD, PhD (Author), Veronica Azemawah PharmD (Author), Lee Peyton PhD (Author), James Gregory BS (Author), Mehrnoosh Hashemzadeh PhD (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
by: Rosaria Vincenza Giglio BD, PhD, et al.
Published: (2023) -
Anticonvulsant Effects of Aerial Parts of Extract in Mice: Involvement of Benzodiazepine and Opioid Receptors
by: Amir Rashidian PharmD, PhD, et al.
Published: (2017) -
Anticonvulsant Effects of Aerial Parts of Extract in Mice: Involvement of Benzodiazepine and Opioid Receptors
by: Amir Rashidian PharmD, PhD, et al.
Published: (2017) -
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
by: Maya Safarova, et al.
Published: (2024) -
Building Community Pharmacy Work System Capacity for Medication Therapy Management
by: Jon C. Schommer, Ph.D, et al.
Published: (2012)